公开(公告)号：US20100190824A1

公开(公告)日：2010-07-29

申请号：US12452389

申请日：2008-06-24

Applicant: Prabhat Kumar ,  Anookh Mohanan ,  Navnath Argade ,  Chakradhar Hadole ,  Appaji Mandhare ,  Ramesh Gupta ,  Shailesh Deshpande ,  Prashant Jamadarkhana ,  Poonam Joshi

Inventor： Prabhat Kumar ,  Anookh Mohanan ,  Navnath Argade ,  Chakradhar Hadole ,  Appaji Mandhare ,  Ramesh Gupta ,  Shailesh Deshpande ,  Prashant Jamadarkhana ,  Poonam Joshi

IPC: A61K31/4545 ,  C07D211/68 ,  A61P25/28 ,  A61P25/08 ,  A61P9/10

CPC classification number: C07D401/06 ,  C07D211/74 ,  C07D409/06 ,  C07D413/06

Abstract: The present invention relates to novel compounds of formula (I) or (II), their pharmaceutically acceptable salts and their hydrates, solvates, stereoisomers, conformers, tautomers, polymorphs and prodrugs and also pharmaceutically acceptable compositions containing them Wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification. The compounds of the present invention are HSP inducers and by virtue of this effect, useful for the treatment of various diseases accompanying pathological stress. The present invention also relates to a process for the preparation of the said novel compounds. The invention also relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.

Abstract translation: 本发明涉及式（I）或（II）的新化合物，其药学上可接受的盐及其水合物，溶剂合物，立体异构体，构象异构体，互变异构体，多晶型物和前药以及含有它们的药学上可接受的组合物。其中R1，R2，R3， R4，R5，R6和R7如说明书中所定义。 本发明的化合物是HSP诱导剂，并且由于这种效果，可用于治疗伴随病理应激的各种疾病。 本发明还涉及制备所述新化合物的方法。 本发明还涉及上述化合物在制备用作药物的药物中的用途。

公开(公告)号：US20070265297A1

公开(公告)日：2007-11-15

申请号：US11547227

申请日：2005-04-01

Applicant: Gregory Bebernitz ,  Ramesh Gupta ,  Vikrant Jagtap ,  Appaji Mandhare ,  Davinder Tuli

Inventor： Gregory Bebernitz ,  Ramesh Gupta ,  Vikrant Jagtap ,  Appaji Mandhare ,  Davinder Tuli

IPC: A61K31/437 ,  A61P3/04 ,  A61P3/10 ,  C07D513/04

CPC classification number: C07D513/04

Abstract: The present invention provides compounds of the formula which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, Type 2 diabetes and obesity.

Abstract translation: 本发明提供了作为葡萄糖激酶活性的激活剂的下式的化合物，因此可用作治疗葡糖激酶介导的病症的治疗剂。 因此，式（I）化合物可用于预防和治疗葡萄糖耐量异常，2型糖尿病和肥胖症。